NanoVibronix Announces Successful Interim Trial Results for UroShield™
Demonstrates efficacy preventing catheter-acquired urinary tract infections
Less than 4% using UroShield™ developed infections versus 52% of control group
ELMSFORD, NY–(Marketwired – November 08, 2017) – NanoVibronix, Inc, (NASDAQ: NAOV), a medical device company utilizing the Company’s proprietary and patented low intensity surface acoustic wave technology, today announced successful interim trial results for its UroShield™ device. UroShield™ is an ultrasound-based product that is designed to prevent bacterial colonization and biofilm on indwelling urinary catheters and increase antibiotic efficacy, ultimately reducing the incidence of catheter-associated urinary tract infections (CAUTI). UroShield is also intended to decrease pain and discomfort associated with urinary catheter use.